As far as we know, this is the first study assessing the influence of pyrrolo[3,4-d]pyridazinone derivatives on Foxp3 and IL-10 expression in experimental colitis, which reveals that preventing the decrease in Foxp3 and IL-10 expression in a proinflammatory molecule environment is insufficient to alleviate the symptoms of inflammation and, presumably, would need to go hand-in-hand with inhibition of proinflammatory mediators [67,72,73]. Here, FOXP3 is linked to colitis.